Other than antihypertensive candesartan benefits with focus on women Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
candesartan, sartans, angiotensin II receptor blockers, hypertension, heart failure, inflammatory brain disorders
Main Article Content
Abstract
Candesartan is a selective angiotensin II AT1 receptor blocker which is widely used in cardiovascular diseases. Cardiovascular diseases are the leading cause of death in the world. High cardiovascular mortality is mainly result of heart failure, hypertension and cerebrovascular disease. This review provides present candesartan position in the cardiovascular disease treatment. We focused on candesartan administration in women and we described the anti-inflammatory properties which might broaden the group of patients treated with candesartan in the future
Article Details
How to Cite
Januszkiewicz, Łukasz, & Grabowski, M. (2017). Other than antihypertensive candesartan benefits with focus on women. Medycyna Faktow (J EBM), 10(2(35), 93-98. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2148
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mozaffarian D., Benjamin E.J., Go A.S. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-322.
2. Chou A.F., Scholle S.H., Weisman C.S. et al.: Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007; 17: 120-130.
3. Gu Q., Burt V.L., Paulose-Ram R., Dillon C.F.: Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 2008; 21: 789-798.
4. Huxley R., Barzi F., Woodward M.: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
5. Huxley R.R., Woodward M.: Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-1305.
6. Kearney P.M., Whelton M., Reynolds K. et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
7. Kitler M.E.: Differences in man and women in coronary artery disease, systemic hypertension and their treatment. Am. J. Cardiol. 1992; 70: 1077-1080.
8. Kim J.K., Alley D., Seeman T. et al.: Recent changes in cardiovascular risk factors among women and men. J. Womenís Health (Larchmont) 2006; 15: 734-746.
9. Wassertheil-Smoller S.: Stroke in women. Nutr. Metab. Cardiovasc. Dis. 2010; 20(6): 419-425.
10. Timaru-Kast R., Wyschkon S., Luh C. et al.: Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 2012; 40: 935-944.
11. Sever P., Michel J., Voet B.: Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 1998; 11(4 Pt 2): 79A.
12. Elmfeldt D., Olofsson B., Meredith P.: The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002; 11(5): 293-301.
13. Himmelmann A., Keinanen-Kiukaanniemi S., Wester A. et al.: The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients w ith mild to moderate hypertension. Blood Press. 2001; 10(1): 43-51.
14. Julius S., Nesbitt S.D., Egan B.M. et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006; 354: 1685-1697.
15. Bell T.P., DeQuattro V., Lasseter K.C. et al.: Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Am. J. Cardiol. 1999; 83(2): 272-275, A6.
16. Lithell P., Hansson L., Skoog I. et al.; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21(5): 875-886.
17. Schrader J., Luders S., Kuschewski A. et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34(7): 1699-1703.
18. Tsukuda K., Mogi M., Iwanami J. et al.: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
19. Li N.C., Lee A., Whitmer R.A. et al.: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
20. Candesartan's Effects on Alzheimer's Disease And Related Biomarkers (CEDAR) [online].
21. CAndesartan vs LIsinopril Effects on the BRain (CALIBREX) [online].
22. Tronvik E., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65-69.
23. Etminan M., Levine M.A., Tomlinson G., Rochon P.A.: Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 2002; 112(8): 642-646.
24. Gulati G., Heck S.L., Ree A.H. et al.: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 2016; 37(21): 1671-1680.
2. Chou A.F., Scholle S.H., Weisman C.S. et al.: Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007; 17: 120-130.
3. Gu Q., Burt V.L., Paulose-Ram R., Dillon C.F.: Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 2008; 21: 789-798.
4. Huxley R., Barzi F., Woodward M.: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
5. Huxley R.R., Woodward M.: Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-1305.
6. Kearney P.M., Whelton M., Reynolds K. et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
7. Kitler M.E.: Differences in man and women in coronary artery disease, systemic hypertension and their treatment. Am. J. Cardiol. 1992; 70: 1077-1080.
8. Kim J.K., Alley D., Seeman T. et al.: Recent changes in cardiovascular risk factors among women and men. J. Womenís Health (Larchmont) 2006; 15: 734-746.
9. Wassertheil-Smoller S.: Stroke in women. Nutr. Metab. Cardiovasc. Dis. 2010; 20(6): 419-425.
10. Timaru-Kast R., Wyschkon S., Luh C. et al.: Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 2012; 40: 935-944.
11. Sever P., Michel J., Voet B.: Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 1998; 11(4 Pt 2): 79A.
12. Elmfeldt D., Olofsson B., Meredith P.: The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002; 11(5): 293-301.
13. Himmelmann A., Keinanen-Kiukaanniemi S., Wester A. et al.: The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients w ith mild to moderate hypertension. Blood Press. 2001; 10(1): 43-51.
14. Julius S., Nesbitt S.D., Egan B.M. et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006; 354: 1685-1697.
15. Bell T.P., DeQuattro V., Lasseter K.C. et al.: Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Am. J. Cardiol. 1999; 83(2): 272-275, A6.
16. Lithell P., Hansson L., Skoog I. et al.; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21(5): 875-886.
17. Schrader J., Luders S., Kuschewski A. et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34(7): 1699-1703.
18. Tsukuda K., Mogi M., Iwanami J. et al.: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
19. Li N.C., Lee A., Whitmer R.A. et al.: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
20. Candesartan's Effects on Alzheimer's Disease And Related Biomarkers (CEDAR) [online].
21. CAndesartan vs LIsinopril Effects on the BRain (CALIBREX) [online].
22. Tronvik E., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65-69.
23. Etminan M., Levine M.A., Tomlinson G., Rochon P.A.: Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 2002; 112(8): 642-646.
24. Gulati G., Heck S.L., Ree A.H. et al.: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 2016; 37(21): 1671-1680.